anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a proliferation and differentiation promoter for hematopoietic cells useful for prophylaxis or improvement in anemia, leukopenia or deterioration of immunological competence due to medical or surgical diseases, medicines, etc. or medical symptoms caused by hematopoietic dysfunction and a food and drink containing the promoter added thereto. SOLUTION: An extracted essence of TOKYU (a resin secreted from the bark of a myrica) has a proliferation activity for T lymphocytes, is capable of promoting the proliferation and diffentiation of polyfunctional hematopoietec stem cells and recovering the reduction in the amounts of luekocytes, erythrocytes, hematocrits and hemoglobin due to the administration of an anticancer agent. The TOKYU used herein includes that derived from peaches of all the cultivable varieties and a David peach, e.g. a common peach (botanical name: Prunus persica Batsch var. vulgaris Maxim.) or varieties such as a nectarine (botanical name: Prunus persica Batsch var. nucipersica Shneid.) or a peento (botanical name: Prunus persica Batsch var. platycarpa L. H.  Bailey) and further the David peach (botanical name: Prunus persica Batsch davidiana Maxim.) or a flowering plum (botanical name: Prunus triloba Lindl., 2n=6). All the TOKYU derived from the varieties is included herein.
The present invention provides a double helix oligo-RNA structure in which target-specific ligands are bonded to the double helix oligo-RNA structure in which high molecular compounds for improving the delivery of double helix oligo-RNA that can be valuably used in treating diseases, specifically, cancer, are covalently bonded. The present invention also provides a method for preparing the RNA structure and a target-specific double helix oligo-RNA delivery technology through said structure. Nanoparticles constituted by the double helix oligo-RNA structure to which ligands are bonded may efficiently deliver double helix oligo-RNA to a target, and thus may exhibit an activity of double helix oligo-RNA structure in a target cell even with an administration of double helix oligo-RNA of relatively lower concentration. The nanoparticles may prevent the delivery of non-specific double helix oligo-RNA to other organs and cells, and therefore, can be valuably used not only as a tool for double helix oligo-RNA for treating various diseases, specifically, cancer, but also as a new type of double helix oligo-RNA delivery system. The present invention also relates to hybrid conjugates in which a hydrophilic material and a hydrophobic material are connected to both ends of antisense oligonucleotide(ASO) through covalent bond so as to achieve in vivo stability of the ASO, and to a method for preparing the hybrid conjugates and to nanoparticles constituted by the conjugates. The conjugates between ASO and macromolecules according to the present invention may improve in vivo stability of ASO, and therefore, can efficiently deliver ASO for treatment into cells and may exhibit an activity of ASO even with an administration of a relatively lower concentration.
Group will receive sciatic catheter placed before or after surgery by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
The aim of our study is to explore the activation of macrophages in patients with ST-segment elevation myocardial infarction (STEMI) or stable angina (SA) using the 18 kDa translocator protein (TSPO) radioligand 18F N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline (18F-PBR06) in combination with the world's first commercially available total-body PET/CT (uExplorer). The investigators expect to enroll 10 patients diagnosed with STEMI and 10 patients with SA who receive coronary angiography (CAG) and the percutaneous coronary intervention (PCI), and 5-10 healthy individuals diagnosed with SA but presenting negative CAG at Renji Hospital, Shanghai. The activation of macrophages (TSPO uptake) and blood perfusion in different organs will be studied using 18F-PBR06/uExplorer.

With written consent from eligible participants, the investigators will review past medical records and document the medical history for each participant. Patients will undergo PCI on the day of enrolment (12 hours within the symptom onset for STEMI patients). Screen procedures will be performed at the seventh day of enrolment (Day 7, D7) and Day 180 (D180). Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 and receive a whole-body scan by uExplorer. TSPO uptake and blood flow in the heart, kidney, liver, brain, and lung will be recorded. All participants will be followed for 1 year after enrolment. Blood samples will be collected and echocardiography will be performed at D7 and D180. Major adverse cardiovascular events (MACE) will be recorded throughout the follow-up.
Toddlers of 1 to 3 years old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
The aim of this online study is the evaluation of healthy behaviors and anxiety levels in relation to selected physical, mental, and environmental health aspects. The umbrella terminology of "planetary health" is used in the context of this study. As climate change progresses at a dangerous rate, it is important to establish and maintain lifestyles that are productive, fulfilling, environmentally conscious, and low in anxiety. By evaluating prevalence of healthy behaviors and levels of eco-anxiety as well as loneliness as one early indicator of health risk, this study hopes to build on existing public health knowledge to develop interventions targeting and encouraging multiple aspects of healthy, eco-friendly lifestyles. This study will also help later intervention design by determining effective methods of persuasion and promotion of sustainable planetary health behaviors. Main research questions are

I. Are climate-sensitive people and rehabilitation patients (in terms of EMCB, YCSCB and Mindful Health) more likely to also promote their own health (in terms of physical activity and healthy nutrition)? II. What is the (non-)linear relationship between eco-anxiety and climate-sensitiveness/health behavior? III. Is climate-sensitiveness and eco-anxiety invariant to partner status, number of people in the household, gender, occupation, and age? (No differences) IV. Is loneliness linked to partner status, number of people in the household and younger age but uncorrelated to eco-anxiety, climate-sensitiveness/health behavior? V. What is the prevalence of loneliness in 2023 in comparison to 2022, 2021, 2020, and 2019? Do people and rehabilitation patients who feel more lonely after the corona pandemic than before show more eco-anxiety and climate-sensitiveness but less healthy behavior than people who feel as/less lonely than prior to the corona pandemic? VI. Is active persuasion involving mental simulation more effective in promoting eco-friendly behaviours than passive persuasion involving information dissemination as measured by the YCSCB and EMCB? (testing two mini interventions) VII. To what extent are medical rehabilitation patients different from the general population?
Female hypogonadism; female castration; primary ovarian failure.

###  USUAL DOSAGE RANGES:

Female hypogonadism – 2.5 to 7.5 mg daily, in divided doses for 20 days, followed by a rest period of 10 days' duration. If bleeding does not occur by the end of this period, the same dosage schedule is repeated. The number of courses of estrogen therapy necessary to produce bleeding may vary depending on responsiveness of the endometrium. If bleeding occurs before the end of the 10 day period, begin a 20 day estrogen-progestin cyclic regimen with Menest (esterified estrogens tablets), 2.5 to 7.5 mg daily in divided doses, for 20 days. During the last 5 days of estrogen therapy, give an oral progestin. If bleeding occurs before this regimen is concluded, therapy is discontinued and may be resumed on the fifth day of bleeding.

Female castration and primary ovarian failure – 1.25 mg daily, cyclically. Adjust dosage upward or downward according to severity of symptoms and response of the patient. For maintenance, adjust dosage to lowest level that will provide effective control.
PROBLEM TO BE SOLVED: To obtain the subject diagnostic agent capable of accurately diagnosing diabetes by the measurement of an increase rate in the concentration of<13> C contained in exhaled CO2 and thereby giving a precise test result substantially without giving a load to the subject by including a glyceride in which a carbon at a specific position is labeled with the<13> C. SOLUTION: This diagnostic agent contains a glyceride in which a carbon at a specific position is labeled with<13> C. The glyceride is preferably trioctanoin, etc. The diagnostic agent preferably contains the glyceride usually in an amount of 1-40 wt.% in the preparation form of an injection, and in an amount of 50-100 wt.% in the preparation form of capsules, tablets, etc. The remainder in the preparation comprises a carrier. The diagnostic agent is administered, for example, at a dose of 1-1,000 mg/kg for an adult. Diabetes are preferably diagnosed by administering the diagnostic agent to a subject, measuring the concentrations of<13> C in exhaled CO2 , and subsequently examining the data of increase rates on the concentrations of the<13> C a constant time later after the administration.  It is more preferable that the expiration test is comprehensively judged in combination with a blood sugar value, etc.
UNLABELLED: Rab GTPases control intracellular vesicular transport, including retrograde trafficking of human papillomavirus (HPV) during cell entry, guiding the virus from the endosome to the trans-Golgi network (TGN), the Golgi apparatus, and eventually the nucleus. Rab proteins have been identified that act prior to the arrival of HPV at the TGN, but Rab proteins operating in later stages of entry remain elusive. Here, we report that knockdown of Rab6a impairs HPV entry by preventing HPV exit from the TGN and impeding intra-Golgi transport of the incoming virus. Rab6a supports HPV trafficking by facilitating the association of HPV with dynein, a motor protein complex, and BICD2, a dynein adaptor, in the TGN. L2 can bind directly to GTP-Rab6a in vitro, and excess of either GTP-Rab6a or GDP-Rab6 inhibits HPV entry, suggesting that cycling between GDP-Rab6 and GTP-Rab6 is critical. Notably, Rab6a is crucial for HPV-BICD2 and HPV-dynein association in the TGN of infected cells but not in the endosome. Our findings reveal important features of the molecular basis of HPV infection, including the discovery that HPV uses different mechanisms to engage dynein at different times during entry, and identify potential targets for therapeutic approaches to inhibit HPV infection.
IMPORTANCE: Human papillomaviruses (HPVs) are small, non-enveloped DNA viruses that cause approximately 5% of human cancer. Like most other DNA viruses, HPV traffics to the nucleus during virus entry to successfully infect cells. We show here that HPV utilizes a cellular enzyme, Rab6a, during virus entry to engage the dynein molecular motor for transport along microtubules. Rab6a is required for complex formation between the HPV L2 capsid protein, dynein, and the dynein adaptor BICD2 in the trans-Golgi network (TGN). This complex is required for transport of the incoming virus out of the TGN as it journeys to the nucleus. Our findings identify potential targets for therapeutic approaches.
1386533 Animal feed additive NAREMCO Inc 13 April 1973 [17 Nov 1972[ 18035/73 Heading A2B An animal or poultry feed additive comprises a finely divided, acid-treated, non-toxic mineral carrier having methyl rosaniline chloride dispersed thereon. The mineral carrier may be a clay or a diatomaceous earth, Ca or Mg carbonate, phosphate or silicate, or organic or inorganic salts e.g. Mg, Cu, Fe, Mn, Co or Zn sulphates, which is preferably useful as a component of an animal feed. The acid may be acetic, citric, propionic, butyric, or lactic acid, or a mineral acid, selected so as not to form water insoluble salts with the mineral carrier. The carrier should pass through a 100 mesh U.S. standard sieve. The methyl rosaniline chloride is dissolved in a volatile organic solvent e.g. alcohol or ketone for dispersion. Preferred quantities are 0.1 to 5% by wt. of methyl rosaniline chloride and 1 to 10% by wt. of acid based on the weight of carrier, when the acid is acetic and the carrier calcium carbonate. The additive may be formed by blending calcium carbonate and diatomaceous silica, dissolving acetic acid and methylrosaniline chloride in methanol, and mixing the rewetting solution with the blended carrier until the methanol has evaporated. 0.1 to 25 lbs of additive is added per ton of feed to prevent mould.
BACKGROUND AND AIM: Piecemeal endoscopic mucosal resection (pEMR) is the best approach to resect large lateral spreading tumors (LST, > 20 mm width). However, it is associated with early recurrence (ER) and late recurrence (LR). This study aims to assess the risk factors associated with ER and LR and to validate different predictive scores (SMSA, SERT, and BCM) in identifying the risk of ER and LR after LST resected by pEMR in a European cohort.
METHODS: Retrospective observational cohort study, based on a prospectively collected database, of large LST submitted to pEMR.
RESULTS: A total of 108 patients were included in the study and the incidence rates of ER and LR were 22 % and 8 %, respectively. The lesion's size, SERT, and BCM scores were independent predictor factors of ER (p-value < 0.05), while the lesion's site and BCM score were independent predictor factors of LR (p-value < 0.05). For the prediction of ER, the SERT score (cut-off > 1) presented the highest AUROC (0.758 vs 0.697 from BCM and 0.647 from SMSA). Regarding LR, the BCM model (cut-off > 2) presented the highest AUROC (0.817 vs 0.708 from SERT and 0.691 from SMSA).
CONCLUSIONS: We present the first external validation of the three scores mentioned in an European cohort. SERT and BCM scores had an acceptable performance in predicting ER and LR. However, the BCM model was the only score that proved to be an independent predictor of both ER and LR, proving to be valuable for both applications.
Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
Chronic endometritis (CE) is a persistent inflammation of the endometrium caused by microbial infection, which is characterized by the infiltration of plasma cells into the endometrial stromal area. CE emerges as a critical determinant in the etiology of female infertility and is closely associated with adverse pregnancy outcomes, such as recurrent spontaneous abortion and repeated implantation failure, imposing a heavy burden on patients and their families. However, current understanding of CE-induced infertility remains superficial, leading to delays and inconsistent approaches in the diagnosis and treatment of the condition. Emphasizing the diagnosis and treatment of CE can help improve women's reproductive health, alleviate the economic and psychological pressures of patients and their families, resolve family conflicts and promote family and social harmony. This article provides an in-depth analysis of the diagnostic criteria and current application status of CE, its impact on endometrial receptivity and fallopian tubal function, as well as its interplay with other gynecological disorders. In alignment with clinical practice, we propose suggestions including enhancing the understanding of CE, strengthening publicity and education, standardizing the diagnostic process for CE, exploring the molecular mechanisms of CE and optimizing treatment strategies, in order to improve the comprehensive diagnosis and treatment strategies of CE-induced infertility and make greater contributions to the reproductive health of women in China.
The enrolled patients will receive a long course of NCRT (50 Gy / 25f, capecitabine 850-1000 mg / m2, BID, PO, D1-D5, QW) within the first 5 weeks. In regard to tumor immunotherapy, enrolled patients will receive tislelizumab (200 mg, iv) on the first day at week 2,5, and 8 after initiation of radiotherapy. Thereafter, patients will be treated with two 14-day cycles of the CAPOX（Q 3 w; D1 oxaliplatin, 130mg/m2,iv.gtt; D1-D14, capecitabine, 850-1000mg / m2, BID, PO）regimen. Two CAOPX regimens were treated one week apart. Eight to 8-10 weeks after the completion of radiation therapy, patients will undergo multiple examinations, including colonoscopy and MRI. Subsequent treatment options will be determined by each center physician based on their clinical experience.
Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Fascia sutured using #1 polysorb braided absorbable suture with a buried knot below the fascia starting at the left angle and closed in a continuous fashion until the suture overlies the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is then tied behind the right angle with a buried knot below the fascia and run across in a continuous fashion to meet the opposing suture which are then tied together.
Meetings with knowledge broker 6 times over 10 months to design and implement knowledge translation intervention. Intervention consisted of audit and feedback, goal setting, education, reminders, documentation changes, and KB support.
Uterine fibroids are benign uterine masses with a prevalence of 70-80% by age 50 in the population. They can cause heavy menstrual bleeding, pelvic discomfort, and may impair fertility. Surgical removal of uterine fibroids (myomectomy) is commonly offered to women who wish to preserve fertility. Myomectomy is often done through laparotomy (open myomectomy), and is often associated with major surgical blood loss and blood transfusion. A recent Cochrane review of interventions to reduce intra-operative blood loss at myomectomy reported a mean estimated blood loss of 151-1047 mL in the non-intervention group, and a 20% rate of blood transfusion. This rate is particularly alarming in this young female population, as blood transfusion confers immediate and long-term risks, including the development of red blood cell antibodies which may be detrimental in future pregnancy.

Perioperative anemia and intraoperative blood loss have been associated with increased morbidity and mortality. Patients with mild to moderate pre-operative anemia (hemoglobin in the range of 80-120 g/L) have an increased association with severe adverse outcomes. Paradoxically, transfusion of red blood cells has also been associated with increased morbidity and mortality in perioperative patients. Thus, both anemia and one of its primary treatments are associated with adverse outcomes. While these outcomes have not been clearly defined in gynecological surgery, patients facing myomectomy are often severely anemic and can suffer severe blood loss for which red blood cell transfusion is the only therapy. Therefore, any approach that reduces both pre-operative anemia and acute intraoperative blood loss may result in improved patient outcomes.

Clinical pathways to reduce surgical blood loss have demonstrated efficacy in the orthopaedic literature. Successful strategies include avoidance of pre-operative anemia and the intra-operative use of a synthetic antifibrinolytic agent (tranexamic acid), with significant reductions in blood loss and transfusion rates during orthopaedic surgery. Similarly, there is evidence in the gynaecologic literature for interventions to reduce major blood loss and blood transfusion at myomectomy (Table 1), including vaginal misoprostol, vaginal dinoprostone, intramyometrial vasopressin, intravenous tranexamic acid, pericervical tourniquet, and fibrin sealant patch. However, there is currently no standardized intra-operative blood conservation pathway, and clinical practice is variable among clinicians. To address this knowledge translation gap, this study aims to develop an intra-operative pathway designed by a multi-disciplinary team of researchers and end-users to reduce major blood loss and transfusion rates at open myomectomy.
This group will receive a weight-maintaining diet with 20% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing \~1x10\^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (\~2x10\^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area.
Assessing the perioperative, oncological, and functional results of robotic-assisted radical prostatectomy (RARP) versus three-dimensional laparoscopic radical prostatectomy (3D LRP), a comprehensive exploration of the Cochrane Library, PubMed, EMBASE, and Web of Science databases was carried out until July 2024. The combined results were evaluated by utilizing the weighted mean differences (WMDs) and odds ratios (ORs) through the application of Stata version 18, where data were gathered and scrutinized. In addition, sensitivity analyses were performed to ensure the robustness of our findings. In the meta-analysis we conducted, four studies were incorporated in total, which comprised two randomized controlled trials, one study that was retrospective and another that was prospective. The findings revealed that RARP was associated with a significantly reduced estimated blood loss (EBL) (WMD - 31.04, 95%CI - 54.57, - 7.51; p = 0.01) compared to 3D LRP. Nonetheless, there were no notable statistical variances seen between the two groups regarding operative time (OT), nerve-sparing rates, positive surgical margin (PSM) rates, biochemical recurrence (BCR) rates, or the restoration of urinary continence and potency 3 or 6 months after the surgery. In conclusion, our comprehensive meta-analysis has offered a detailed contrast between the results of RARP and 3D LRP in the treatment of prostate cancer. The findings highlight a considerable decrease in projected blood loss linked with RARP, yet no notable variances were detected between the two methods regarding other perioperative, oncological, and functional results.